Genes in panel
STRs in panel
Prev Next
Regions in panel
Prev Next

BabyScreen+ newborn screening

Gene: RB1

Green List (high evidence)

RB1 (RB transcriptional corepressor 1)
EnsemblGeneIds (GRCh38): ENSG00000139687
EnsemblGeneIds (GRCh37): ENSG00000139687
OMIM: 614041, Gene2Phenotype
RB1 is in 9 panels

1 review

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

Well established gene-disease association.

Rated as 'strong actionability' in paediatric patients by ClinGen.

Rb is a is life- and vision-threatening childhood cancer. Roughly 60% of affected individuals have a unilateral Rb (if one eye is affected), which is usually unifocal. Roughly 40% have bilateral Rb (if both eyes are affected). Some cases are trilateral where bilateral Rb (or rarely unilateral) and a pinealoblastoma co-occur.

Individuals with unilateral and bilateral Rb have a mean diagnosis ages of 24 and 15 months, respectively. The majority of Rb cases are detected before 5 years. If left untreated, Rb is fatal. With timely screening, diagnosis, referral, treatment, and follow-up delivered in a systematic way by a multidisciplinary team, 95 – 98% of children with Rb are cured, many with useful vision. Ocular survival rate is significantly lower when the presenting sign is leukocoria (8.5% over 5 years), rather than strabismus (17% over 5 years). Prognosis of trilateral Rb remains poor, with most patients dying from progressive disease within 2 years of diagnosis.

Clinical screening, including examination by an ophthalmologist with experience in Rb, begins at birth and is lifelong. Screening is initiated with examination by an ophthalmologist with experience in Rb beginning at birth and going to 5 years of age, by way of the red reflex test and the Hirschberg test. If these tests yield abnormal results, it is recommended that a pediatric anesthetist provide frequent examinations under anesthesia (EUAs). Early diagnosis, when tumors are small, maximizes survival and vision outcomes and reduces the need for chemotherapy, enucleation, and radiotherapy.
Created: 15 Dec 2022, 1:30 a.m. | Last Modified: 15 Dec 2022, 1:30 a.m.
Panel Version: 0.1479

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Retinoblastoma, MIM# 180200

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Green
  • BabySeq Category A gene
Phenotypes
  • Retinoblastoma, MIM# 180200
Tags
cancer treatable
OMIM
614041
Clinvar variants
Variants in RB1
Penetrance
None
Panels with this gene

History Filter Activity

17 Jan 2023, Gel status: 3

Removed Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review was removed from gene: RB1.

15 Dec 2022, Gel status: 3

Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review tag was added to gene: RB1.

15 Dec 2022, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: rb1 has been classified as Green List (High Evidence).

15 Dec 2022, Gel status: 3

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: RB1 were changed from Retinoblastoma to Retinoblastoma, MIM# 180200

15 Dec 2022, Gel status: 3

Added Tag, Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag cancer tag was added to gene: RB1. Tag treatable tag was added to gene: RB1.

18 Sep 2022, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: RB1 was added gene: RB1 was added to gNBS. Sources: BabySeq Category A gene,Expert Review Green Mode of inheritance for gene: RB1 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: RB1 were set to Retinoblastoma